Thank you for contacting GLG, someone will respond to your inquiry as soon as possible.

SURVEY DETAILS

TARGET POPULATION

For this Network Survey, GLG surveyed 90 pharma and biotech CDMO decision makers from US, Europe (UK, France, Germany, Italy, Spain) and APAC (China, Australia, Singapore and Korea). This is the second iteration in this tracker series.

What will you learn from this survey?

  • Respondents evaluated key players including large molecule CDMOs such as Lonza, Catalent, Samsung Biologics, and Wuxi Biologics, and trending players among small molecule CDMOs such as Siegfried, Syngene, Wuxi Apptec, and Piramal.
  • The respondents also commented on their current CDMO outsourcing including the outsourcing proportion, type of products outsourced, distribution among geographies, and how this is expected to change in the future.
  • Lastly, the survey looked into the factors for selecting a CDMO provider, likelihood of various types of projects to be outsourced to major CDMOs, performance of CDMOs on various criteria, as well as change in pricing and service quality in the industry over the last few years.

Examples of findings:

  • Over four-in-ten respondents declared to be currently using Lonza (42%) and Catalent (41%) as their CDMOs.
  • Quality issues continue to be the main reason for changing CDMOs for over eight-in-ten (83%) respondents.
  • Four-in-ten (40%) respondents selected small molecule API, reporting it to be the most outsourced product in July 2024.

Deliverables

The GLG Surveys team drafted the questionnaire with the support of GLG Network Member, Guido Dietrich, Former VP of Global Quality Assurance at Merck, Lonza and GSK.

  • 1 x Individual responses (“raw data”) in Excel.
  • 1 x PPT report with aggregated data.
  • Executive summary with key takeaways and highlights from the raw data.

Sample Questions

  • Overall, what percentage of the following products do you currently outsource to CDMOs?
  • In your opinion, how has CDMO service quality changed over the last 5 years at the industry level?
  • Over the last five years, how did pricing for CDMO services evolve?
  • How do you view the available capacity for CDMO services today?
  • Over the next years, how do you foresee the total usage of the below CDMO(s) to change?
  • What is the geographic mix of your outsourcing spend? What was it 24 months back and how does it look like 12-24 months from now?
  • What would be the key reasons to switch a CDMO provider? Please rank up to 3 where 1 being the most important reason.

Access

This survey is available to subscribers of the Healthcare (HC) sector (Limited subscriptions and above). This offer includes the raw data file and a high-level presentation through PowerPoint. Please contact your GLG representative for details on your firm’s access.

 

DISCLAIMER

Please be advised that GLG Network Surveys operate differently than traditional GLG consultations, surveys, teleconferences, etc. and it is advisable that you consult with your firm’s legal and/or compliance department to review your use of the product and the payment for such work under your current subscription. 

By downloading this document and/or participating in the Network Survey, you understand and agree that the information and material provided by GLG, including survey results and survey proposal information, is provided for your own insight and informational purposes only. You further acknowledge and agree that this is a Network Survey for multiple GLG clients, and the results will be provided to all GLG clients that agree to participate in the Network Survey and GLG clients that agree to purchase the Survey results in the future. All survey results do not constitute investment advice or a recommendation. In using this Survey, you agree to hold Gerson Lehrman Group and the Survey respondents harmless and free of all liability as a result of your use of this Network Survey, other than liability resulting from the gross negligence or wilful misconduct of the protected party. You otherwise agree to be bound by Gerson Lehrman Group’s Usage Policies in your interactions with Gerson Lehrman Group and your receipt of services. These Survey results are for are for client’s own use and client shall not redistribute, disseminate, publish, or display the same, in whole or in part, to any third parties or publicly without the prior written permission of Gerson Lehrman Group, except explicitly set forth in your agreement with GLG. This survey will be double-blinded to both client and respondent. GLG reserves the right to restrict the number of clients that can pre-commit access. These Network Surveys are priced outside of standard GLG subscriptions but at a substantially reduced price to commissioning a fully proprietary GLG Network Survey. Upon finding these terms acceptable, please send an affirmative confirmation via email, which GLG will file in its records. Once confirmed, please note that the Client’s agreement to purchase the Network Survey is a legally binding and irrevocable commitment. If the survey is not included within your subscription, GLG will invoice Client for the fees due for the Network Survey. Please note that some respondents may not be Network Members, and the Terms and Conditions of Network Membership would not apply to such respondents and detailed records for them will not be available aside from the information that GLG capture in the Network Survey.